WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanoma.

ABSTRACT:

Purpose

Despite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAF^Mut) have a worse prognosis than those with wildtype (BRAF^WT) tumors. Unexpectedly, interim AVAST-M Phase III trial data reported benefit from adjuvant anti-VEGF bevacizumab only in the BRAF^Mut group. We sought to find mechanisms underpinning this sensitivity.

Methods

We investigated this finding in vitro and in vivo using melanoma cell lines and clones generated by BRAF^V600E knock-in on a BRAF^WT background.

Results

Compared with BRAF^WT cells, isogenic BRAF^V600E clones secreted more VEGF and exhibited accelerated growt

SUBMITTER: Coupe N 

PROVIDER: S-EPMC10060292 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature